Angiotech gets FDA clearance for embolism filter

06/8/2009 | Boston Globe (tiered subscription model), The

Angiotech Pharmaceuticals has received marketing approval from the FDA for Option Inferior Vena Cava filter, which can be permanently or temporarily implanted to prevent periodic pulmonary embolism. The company expects the market for the device to reach about $300 million by 2012.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC